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Summary
Linkage disequilibrium (LD) analysis has been promoted
as a method of mapping disease genes, particularly in
isolated populations, but has not yet been used for ge-
nome-screening studies of complex disorders.Wepresent
results of a study to investigate the feasibility of LD
methods for genome screening using a sample of indi-
viduals affected with severe bipolar mood disorder (BP-
I), from an isolated population of the Costa Rican cen-
tral valley. Forty-eight patients with BP-I were genotyped
for markers spaced at ∼6-cM intervals across chromo-
some 18. Chromosome 18 was chosen because a pre-
vious genome-screening linkage study of two Costa Ri-
can families had suggested a BP-I locus on this
chromosome. Results of the current study suggest that
LD methods will be useful for mapping BP-I in a larger
sample. The results also support previously reported
possible localizations (obtained from a separate collec-
tion of patients) of BP-I–susceptibility genes at two dis-
tinct sites on this chromosome. Current limitations of
LD screening for identifying loci for complex traits are
discussed, and recommendations are made for future
research with these methods.
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Introduction
Identifying genes for disorders with complex inheritance
patterns is one of the greatest challenges in biomedical
research (Lander and Schork 1994). Such disorders,
which include many of the most prevalent human dis-
eases, are difficult to map with standard linkage meth-
ods. It has been suggested that the availability of dense
marker maps covering the genome will make linkage
disequilibrium (LD) analysis a feasible approach for
screening the genome to map complex disorders (Risch
and Merikangas 1996). Current marker maps are not
sufficiently dense to enable such studies to be performed
in heterogeneous populations or in populations that
were founded in the distant past. However, the success
of genome-screening LD-mapping studies of genetically
simple and/or rare diseases in recently founded isolated
populations (Houwen et al. 1994; Puffenberger et al.
1994; Friedman et al. 1995; Newport et al. 1996) pro-
vide the impetus for testing the utility of LD methods
for mapping complex diseases in such populations (Es-
camilla et al. 1996). In populations where randomly
sampled patients are on average !20 generations re-
moved from their last common ancestor, LD may be
maintained for sizable regions around disease genes.
Such LD should be manifested by affected individuals
sharing alleles, identical by descent (IBD), at markers
spaced at intervals of several centimorgans surrounding
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a disease gene. We now present the results from the first
stage of a study in which LD methods were used to
screen for loci that predispose to severe bipolar mood
disorder (BP-I), which is common and is almost certainly
characterized by a complex mode of inheritance. The
study was done in a relatively recently founded isolated
population, that of the central valley of Costa Rica
(CVCR) (Escamilla et al. 1996), where founder effects
have already been observed for several inherited diseases
(Saborio 1992; Uhrhammer et al. 1995; Shah et al.
1997).
Despite long-standing evidence that BP-I has a genetic
basis (Escamilla et al. 1997), genome scans for linkage
have provided equivocal results (Risch and Botstein
1996; Nurnberger et al. 1997) that fail to satisfy the
levels of significance suggested for genomewide screens
by Lander and Kruglyak (1995). The failure to identify
BP-I loci definitively, by standard linkage approaches,
probably reflects uncertainty regarding mode of inheri-
tance, high phenocopy rates, difficulty in demarcation
of distinct phenotypes, and presumed genetic heteroge-
neity. LD-based mapping approaches within population
isolates may offer a means of diminishing several of these
obstacles. An approach (such as LD mapping) that sam-
ples individuals from an entire population can more eas-
ily ascertain a large set of patients with a narrowly de-
fined, reliably diagnosed phenotype (in this case, BP-I)
than linkage-based approaches that require ascertain-
ment of family units with multiple affected cases.Within
a population isolate, genetic heterogeneity of BP-I may
also be less than in larger, genetically mixed populations,
as there is a high probability that individuals with such
a phenotype share descent from a few common
ancestors.
We collected a sample of patients with BP-I, for LD
analysis, by identifying individuals currently living in the
CVCR who had known CVCR ancestry. This sample
was collected independently of our previous pedigree-
based studies of BP-I in Costa Rica. Our aim in the
current study was to evaluate the feasibility of identi-
fying BP-I loci by LD screening in this population, as
proposed in Escamilla et al. (1996). To do this, we con-
ducted an LD screen of an entire single chromosome
(chromosome 18). This chromosome was chosen be-
cause previous linkage studies in Costa Rica and in other
populations suggested that it possibly contained bipolar
disorder loci (Berretini et al. 1994; Stine et al. 1995;
Freimer et al. 1996a). Genealogical studies indicated that
the individuals in our current study did not share com-
mon ancestry over the past several generations (Escam-
illa et al. 1996). We therefore anticipated that we would
not detect random genome regions shared IBD by more
than a few individuals and that regions of high IBD
sharing would thus be areas containing possible BP-
I–susceptibility genes inherited from a common founder.
Samples and Methods
Sample Collection
To diminish the likelihood of investigating phenocop-
ies, we limited the sample to individuals with a definite
diagnosis of BP-I, with onset by age 50 years and a
history of at least two psychiatric hospitalizations. The
48 patients with BP-I (25 female patients and 23 male
patients) in the current study were recruited indepen-
dently from psychiatric hospitals and clinics in the
CVCR. First-degree relatives of patients were also re-
cruited, to determine genetic phase. The study was ap-
proved by institutional review boards at the Costa Rican
Ministry of Health, the University of Costa Rica, and
the University of California at San Francisco, and in-
formed consent was obtained from all participating sub-
jects. Of the 48 BP-I subjects, 8 individuals had both
parents available for genotyping, 20 individuals had one
parent available, 10 individuals had one or more chil-
dren available, 1 individual had two siblings available,
and 9 individuals had no relatives available. In nuclear
families, only one individual (the proband) was desig-
nated as affected, and all others were considered to have
unknown phenotype. Details of ascertainment and di-
agnostic procedures, and the clinical and genealogic pro-
files of the study sample, can be found in Escamilla et
al. (1996).
Genotyping
We used 26 markers, spanning chromosome 18, to
genotype all 48 affected individuals (as well as 53 rel-
atives, to establish phase). Of the 25 regions, 21 were
6 cM, and 4 were 6–7 cM. The average distance be-
tween markers was 4.8 cM. When choices were avail-
able, we chose the most polymorphic marker (Gyapay
et al. 1994). The average heterozygosity of the markers
used in this screen (in the CEPH pedigree collection) was
0.75. (The only screening markers with heterozygosity
values !0.70 were D18S464, D18S60, D18S378, and
D18S469.) We screened chromosome 18 at a marker
density of 6 cM because available marker maps had gaps
6 cM, and our goal was to have an equal density of
coverage across the chromosome (Gyapay et al. 1994).
We chose markers from the maps available, at the time
of the study, from Ge´ne´thon (Gyapay et al. 1994), the
Cooperative Human Linkage Center (Murray et al.
1994), and the public database of the Utah Center for
Genome Research. Genotyping procedures used for all
experiments were as previously described by Di Rienzo
et al. (1994). In brief, one of the two primers was labeled
radioactively with a polynucleotide kinase, and PCR
products were separated, by electrophoresis, onto poly-
acrylamide gels. Autoradiographs were scored indepen-
dently by two raters. Data for each marker were entered
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into the computer database twice, and the resultant files
were compared for discrepancies. Scoring was done
without knowledge of affected status.
Simulations
We conducted simulations to evaluate the power of a
likelihood-based test of LD (Terwilliger 1995), to detect
a result significant at the .05 level, with these assump-
tions: a 6-cM marker map; a disease gene in the middle
of the 6-cM segment; affected subjects, with one copy
of the disease gene, separated by 10 generations from a
common ancestor; and four equally frequent marker al-
leles at each marker site. (The disease gene was associ-
ated with the “1” allele at the marker locus.) Under these
assumptions, and with a phenocopy rate of 0%, normal
chromosomes carried each marker allele with a proba-
bility of 25% (normal-chromosome distribution), and
disease chromosomes carried the “1” allele with a prob-
ability of 80%. The probability of disease-chromosome
distribution was calculated with the formula (1
where v  recombinationG Gv)  [1 (1 v) # f ],
fraction, G  number of generations from a common
ancestor, and f the frequency of the allele in the pop-
ulation. Thus, the disease chromosomes carry the “1”
allele with a probability of 80% and each of the re-
maining three alleles with a probability of 6.7%. Because
the true genetic structure of bipolar disorder is unknown,
we examined several different conditions of etiologic het-
erogeneity (which would include locus and allelic het-
erogeneity, as well as phenocopies). We investigated phe-
nocopy rates of 0%, 33%, and 67% (with phenocopy
rates of 33% and 67%, the percentages of chromosomes
from affecteds with the “1” allele are 62% and 43%,
respectively). If an affected individual was randomly se-
lected as a phenocopy (with a probability equal to the
phenocopy rate), then the marker allele on all four pa-
rental chromosomes was randomly chosen from the nor-
mal chromosome distribution. If the affected individual
was randomly chosen as a true case, (with a probability
of 1 minus the phenocopy rate) the marker allele for
one chromosome of that individual was randomly cho-
sen from the normal chromosome distribution, and the
other chromosome’s marker alleles were randomly cho-
sen from the disease-chromosome distribution. Recom-
bination occurred on parental chromosomes in propor-
tion to the marker map. Marker alleles for
nontransmitted chromosomes of the parents were ran-
domly chosen from the normal chromosome distribu-
tion. We performed these analyses by using the 48 pa-
tients with BP-I plus their available relatives. One
hundred replications were performed for each simula-
tion. Available relatives were considered to have un-
known disease phenotype. For the 10 affected individ-
uals with at least one child available for genotyping, one
chromosome from the affected parent was randomly
simulated to be transmitted to available children, and
the other chromosome was randomly selected from the
normal chromosome distribution. Although data were
simulated for parents of all affected individuals, if par-
ents were not available for genotyping, their simulated
genotypes were not used in these analyses.
We also did power simulations (100 replications for
each model) of larger sample sizes, using an ideal situ-
ation in which both parents are available for genotyping,
to aid in planning future studies. In these simulations
we used sample sizes of 90, 200, 300, and 400 affected
individuals; phenocopy rates of 50% and 75%; and a
marker map of 2.5 cM, with all other assumptions as
described above. With this denser marker map, at a phe-
nocopy rate of 0%, disease chromosomes carried the
“1” allele with a probability of 90%, calculated by the
formula and each of theG G(1 v)  [1 (1 v) # f ],
remaining three alleles with a probability of 3.3%. De-
tails of the likelihood-ratio test used in analyzing sim-
ulation results are described inAnalysis.
Analysis
We used two different procedures to identify regions
potentially shared IBD by patients with BP-I. The first
approach, a search for shared segments, has the advan-
tage of being nonparametric. The second approach, al-
though requiring parameters of the illness to be specified,
has the advantage of providing a formal test statistic,
allowing for the calculation of P values. These two tests
thus offer compensatory strengths and weaknesses when
used in the search for genes in a complex disease.
We first searched for shared segments (Houwen et al.
1994). For each individual, we evaluated two marker
haplotypes in each of the 25 intermarker intervals, by
using a preselected threshold (the possible sharing of a
haplotype by 50% of patients) to select segments for
further investigation. Since this screen does not differ-
entiate between sharing that is IBD and sharing that is
identical by state (IBS), use of lower thresholds would
lead to too many segments passing the screen.
We also applied a likelihood-ratio test for LD to each
of the 26 initially tested markers. This test was done
independently of the results of the shared-segment eval-
uation. We applied a modified version of the procedure
of Terwilliger (1995), which only includes case and con-
trol chromosomes or chromosomes transmitted and not
transmitted to patients. In our sample there were several
affected individuals whose parents were not available
but whose children were available. DNA from these lat-
ter individuals could not be analyzed with the original
Terwilliger program but could be analyzed with our im-
plementation of the same procedure, as described by
Freimer et al. (1996a). This procedure examines the like-
lihood that a particular allele (or alleles) is (are) over-
represented on disease chromosomes compared with
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Table 1
Heterozygosity of Markers Used in the Genome Screen of
Chromosome 18
Marker Name
Heterozygosity in
Ge´ne´thon Database
Heterozygosity in
Costa Rican Samplea
D18S1140 .49 .39
D18S59b .81 .81
D18S476b .76 .62
D18S481 .76 .74
D18S391 .75 .69
D18S452 .83 .85
D18S843 NA .73
D18S464 .65 .51
D18S1153 .78 .69
D18S378 NA .54
D18S53 .79 .81
D18S453 .82 .81
D18S40 NA .81
D18S66 .85 .81
D18S56 .73 .74
D18S57 .87 .85
D18S467b .73 .64
D18S460 .62 .67
D18S450 .79 .74
D18S474 .82 .73
D18S69 .79 .78
D18S64 .74 .65
D18S1134 .73 .68
D18S1147 .85 .86
D18S60 .37 .58
D18S55 .77 .80
D18S68 .79 .79
D18S477 .62 .70
D18S61b .87 .86
D18S488 .87 .82
D18S485b .79 .79
D18S541 NA .63
D18S870b NA .66
D18S469b .65 .64
D18S874 NA .64
D18S380 NA .63
D18S1121b .74 .77
D18S1009 .74 .66
D18S844 NA .76
D18S554 .82 .79
D18S461 .77 .65
D18S70 .83 .86
NOTE.—NA  data not available.
a Allele frequencies were calculated from the entire sample, ac-
counting for known relationships among individuals.
b Markers with -2ln(LR) 11.0.
nondisease chromosomes (Terwilliger 1995; Freimer et
al. 1996a). A single parameter, l, is estimated, which
quantifies such overrepresentation of marker alleles on
disease chromosomes. Designation of chromosomes of
probands as disease carrying or non–disease carrying
was achieved by specification of a genetic model for the
disease. The same model of transmission was used in
this LD-likelihood test as was used in the initial genome
screen of the Costa Rican families, described inMcInnes
et al. (1996). In brief, this model assumes that the disease
is nearly dominant (assuming penetrance of .81 for het-
erozygous individuals and .90 for homozygous individ-
uals with the disease mutation), that the population
prevalence of BP-I in Costa Rica is .015, and that the
frequency of the disease gene in the population is .003.
In the likelihood calculations, all possible disease-ge-
notype combinations of all relatives are considered.With
the model that was used, in which the disease-gene fre-
quency is very low, the LD-likelihood test, in most cases,
treats the probands as effectively heterozygous at the
disease locus, and chromosomes of other relatives not
occurring in the probands are treated as non–disease-
carrying chromosomes. We did not specify a phenocopy
rate in the genetic model, because the effect of pheno-
copies will be absorbed by the parameter l; the presence
of phenocopies in our sample will serve to erode the
association between marker alleles and disease and
hence will reduce the estimate of l. Because, in the pre-
sent LD study, we were attempting to gather further
evidence regarding the findings published in our initial
genome screen, we limited ourselves to this one model
in performing the likelihood analyses. However, both
the BP-I family sample and the current LD sample will
ultimately be analyzed with use of other models. We
considered as promising those markers that gave evi-
dence of overrepresentation of an allele on affected chro-
mosomes, with a 2ln(likelihood ratio [LR]) statistic
11.0.
Follow-up genotyping and LD-analysis studies were
performed on markers that gave suggestive findings in
the shared-segment evaluation. Within each segment
that passed the threshold described above, 1–3 addi-
tional markers were typed to permit us to test for LD
across regions of 1–2 cM. Markers that provided sug-
gestive evidence of LD by the initial likelihood-ratio test,
but had not been suggested as promising by the shared-
segment screen, were also followed up, in this case by
typing two additional nearby markers. In all, a total of
42 markers from chromosome 18 were used to genotype
the study sample (table 1 and fig. 1). LD analysis of the
additionally typed markers was conducted by use of the
likelihood-ratio test.
Results
Simulations
Simulation results for the sample of 48 patients with
BP-I and available relatives showed relatively high power
to detect suggestions of association ( ) with lowP  .05
phenocopy rates (94% for a phenocopy rate of 0%, and
54% for a phenocopy rate of 33%) but a dramatically
decreased power under high phenocopy rates (e.g., 9%
for a phenocopy rate of 67%). Additional simulations
showed that, under higher phenocopy rates, the power
to detect LD can be improved by increasing the sample
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Figure 1 Results from the LD screen of chromosome 18. The
26 markers used in the first stage of the screen are listed in the right
column. Sixteen markers used to follow up interesting regions are listed
in the left column. Approximate chromosomal locations of the 26
initial markers and the 16 follow-up markers are indicated by long
and short tick marks, respectively. The eight segments that passed the
initial screen threshold for segment sharing (50% of individuals or
25% of chromosomes sharing a two-marker haplotype) and the five
markers that passed the initial threshold for the Terwilliger LR test
(2ln[LR] 1 1.0) are indicated by blackened bars and asterisks, re-
spectively. Two marker segments that passed the initial threshold were
followed up by at least one marker within the segment, if possible (at
the time of the study no markers were available between D18S843
and D18S464, and only one marker was available between D18S464
and D18S378). Markers that passed the initial threshold for the Ter-
williger LR test were followed up with two additional markers. These
additional markers flanked the original finding. The value of the
2ln(LR) statistic, from the Terwilliger test, is plotted as a solid bar.
This statistic is distributed as a one-sided x2 random variable with one
degree of freedom. The estimate of the l value, for the eight markers
with positive results, is indicated in parentheses after the 2ln(LR)
statistic. Markers without a 2ln(LR) statistic plotted had estimates
of , with the exception of three markers that had estimates ofl  0
.0 ! l ! 0.62
Table 2
Power-of-Likelihood–Analysis Test of LD
POWER TO DETECT LD FOR
SAMPLE SIZE (N) 
PENOCOPY RATE 90 200 300 400
50% 82% 99% 100% 100%
75% 33% 62% 82% 90%
NOTE.—Assumptions included that subjects were removed from a
common ancestor by 10 generations, that a marker map of 2.5 cM
was used, and that each marker had four equally frequent alleles.
Values are the percentage of replicates to have P values !.05.
size and/or the marker density of screening (table 2). For
instance, with a phenocopy rate of 75%, the power in-
creases to 82%with a sample of 300 affected individuals
and a 2.5-cM marker map.
Shared-Segment Screen
We evaluated 25 possible shared segments (defined by
the 26 markers genotyped in the sample). Eight regions
passed the threshold of possible IBD sharing by 50%
of patients. These regions were bounded by the following
markers: D18S843-D18S464, D18S464-D18S378,
D18S467-D18S474, D18S64-D18S60, D18S60-
D18S68, D18S485-D18S469, D18S469-D18S1009, and
D18S1009-D18S461 (fig. 1).
Linkage-Disequilibrium Testing
Five (D18S59, D18S467, D18S61, D18S485, and
D18S469) of the original 26 markers displayed evidence
of possible LD, by means of a likelihood procedure
(2ln[LR] statistic 11.0; table 3). Two (D18S59 and
D18S61) of these five markers had not been identified
as markers of interest by the shared-segment evaluation.
D18S59, located near 18pter, displayed the strongest
pointwise evidence for LD (2ln[LR] statistic of 8.3,
) of all the markers tested in this sample.P  .002
Follow-up of Initial Results
Using the protocol discussed in Samples andMethods,
we genotyped additional markers within the segments
that passed the shared-segment screen as well as follow-
up markers surrounding one (D18S59) of the two mark-
ers that had passed only the LD screen. We were unable
to follow up one shared-segment region (D18S843-
D18S464), because additional polymorphic markers
were not available within the segment. We were also
unable to follow up the finding for D18S61, for the same
reason. Three (D18S476, D18S870, and D18S1121) of
the 16 follow-up markers typed displayed additional ev-
idence of possible LD (fig. 1).
These additional results brought to eight the total
number of markers with 21n(LR) statistics 11.0 (table
3). Five of these eight marker loci were clustered within
a small region of 18q22-23. The most significant LD in
18q22-23 was observed at D18S1121, with 2ln(LR)
of 5.03 and , and two were in 18pter.P  .01
For the two 18pter markers (D18S59 and D18S476),
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Table 3
Frequencies of Marker Alleles Overrepresented in Disease
Chromosomes, as Compared with Nondisease Chromosomes, for
Markers Where -2ln(LR) 11.0
FREQUENCY ON
MARKER ALLELE
Nondisease
Chromosomes
Disease
Chromosomes
D18S59a 154 .121 .572
D18S476 271 .470 .771
D18S467a 172 .384 .693
D18S61a 177 .074 .326
D18S485a 182 .237 .586
D18S870 179 .405 .657
D18S469a 234 .128 .450
D18S1121 168 .171 .553
a Markers from the screening stage.
the alleles overrepresented on BP-I chromosomes (154
and 271 bp, respectively) form a haplotype that occurs
in 48% of the patients with BP-I. Overall, this haplotype
occurs on 26% of the chromosomes of individuals with
BP-I and on 4% of the chromosomes not transmitted
from parents to individuals with BP-I (definite phase for
these two markers could be assigned in 25 patients with
BP-I [50 chromosomes] and 25 nontransmitted parental
chromosomes). Because the composite genetic and phys-
ical maps of the 18q22-23 region had not yet been com-
pleted at the time of this study, the relative order of the
five markers in 18q22-23, for which evidence of LD was
observed, was still too uncertain to permit construction
of definitive marker haplotypes in our study sample.
Marker D18S467, in the 18q12.3 region, was the one
marker outside 18q22-23 and 18pter to show a
2ln(LR) 11 (2ln[LR] 2.5, ). The additionalP  .06
markers used to follow up this result (D18S450,
D18S460, and D18S57) displayed no evidence of
association.
Marker Heterozygosity in the Costa Rican Sample
We calculated heterozygosity values for the markers
used, on the basis of the allele frequencies, estimated
from the entire sample, accounting for known relation-
ships among individuals. These heterozygosities are
shown in table 1, along with the corresponding hetero-
zygosity values of these markers in the CEPH popula-
tion, used by Ge´ne´thon.
Discussion
Screening for Complex Disease Loci by LD
Approaches
Our intention in this work was to explore the feasi-
bility of using LD methods to screen the genome for
susceptibility genes for a common, genetically complex
disorder. The results obtained in our LD-based search
for possible BP-I gene–loci on chromosome 18 were en-
couraging (specific susceptibility regions were sug-
gested), but they highlight a number of issues that must
be considered before LD screening is widely adopted.
Successful application of a shared-segment approach
to any LD study depends on (1) a marker-map density
that is appropriate to the age of the population isolate
being studied and (2) a sharing threshold that will not
be too high to allow true IBD areas to be identified and
that will not be so low as to include many areas that
are IBS false-positive signals. An appropriate marker
map for an LD-screening study should have segments of
a size expected to be shared IBD by many of the affected
individuals. In addition to the density of the marker map
used, the number of generations separating affected in-
dividuals from their common ancestor and the rate of
etiologic heterogeneity in the population will also influ-
ence the choice of the sharing threshold, used to trigger
further study. For example, if the common (disease–gene
bearing) ancestor is removed from the current descen-
dants by 110 generations, the length of true IBD hap-
lotypes shared by 50% of the descendants may be !5
cM (and certainly !6 cM, as is the screen used in this
study) (Te Meerman et al. 1994; Durham and Feingold
1997). Our choice of a threshold of 50% of affected
individuals sharing a possible haplotype therefore effec-
tively meant that we were likely to identify only BP-I
genes of a major effect in this population (phenocopy
rate approaching zero), and even then, only if the dis-
tance from a common ancestor is not 1 ∼10 generations.
Although this was probably too stringent a screen
threshold, given the complex etiology of bipolar disor-
der, the alternative we faced—reducing the threshold to
a lower percentage of potential IBD sharing—would
have drastically decreased the specificity (and hence the
utility) of the screen. For instance, in this particular
study, lowering the threshold to a possible IBD haplo-
type shared in25% of the patients would have resulted
in 24 of the 25 regions tested being determined as regions
of interest. If, in future studies, definite phase infor-
mation can be set for a greater proportion of the pro-
bands (obtained from phasing information supplied by
additional relatives) the “possible IBD” threshold will
be more useful as a screening criterion at thresholds ap-
proaching 25% sharing (almost one in five of the pa-
tients with BP-I in the current study had no relative
available for phase construction). Finally, regardless of
the threshold chosen, there is no widely accepted statis-
tical test available to evaluate the significance of the
number of shared haplotypes observed, although several
statistical approaches are under development (reviewed
by Kruglyak 1997).
The use of markers with low heterozygosity will in-
crease the number of false-positive results in a shared-
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segment screen, as some regions may pass the threshold
because of IBS sharing of a common allele. For example,
the four regions that passed our shared-segment screen,
but gave no evidence of LD in the likelihood-ratio tests
(D18S843-D18S464, D18S464-D18S378, D18S64-
D18S60, and D18S60-D18S68), included markers that
had relatively low heterozygosities in the study popu-
lation (D18S464, D18S60, and D18S378; table 1).
There are two ways to overcome the limitations of
shared-segment analysis, as seen in this study. The first
is to increase the density of markers in the initial screen
(i.e., increase the proportion of BP-I individuals in whom
a shared haplotype can be detected, thus decreasing the
number of false-negative results). Second, future screen-
ing studies may focus on individuals who have available
parents (i.e., increase the number of patients for whom
we can set phase, thus allowing the threshold to be low-
ered in a meaningful way and decreasing the number of
false-positive results).
For a formal statistical test of LD, we used the like-
lihood-ratio test rather than another frequently used
method, the transmission disequilibrium test (TDT)
(Spielman et al. 1993), because data from all 48 patients
with BP-I could be used in the likelihood approach. Ef-
fective use of the original TDT requires parental geno-
types, which were unavailable for 20 of the 48 patients
with BP-I. One potential source of false-negative results,
in our application of the likelihood-ratio test for LD, is
that it is dependent on the specific genetic model for the
disease used in the analysis. For instance, the results of
the likelihood analysis presented here are applicable only
to transmission of dominantly inherited BP-I genes in
the CVCR population. The power of the likelihood test
is also critically dependent on the polymorphism content
of the markers tested and the density of the markers
used for a screening analysis.
Evaluation of Potential BP-I Loci on Chromosome 18
Our previous linkage study of BP-I in two Costa Rican
pedigrees had provided several possible localizations for
BP-I, throughout the genome. Since the 48 Costa Rican
patients in the present study (collected independently of
the pedigree studies and with no known relation to the
pedigree members) are descended from the same ances-
tral population as the patients in those pedigrees (CR001
and CR004; Freimer et al. 1996b), we had reasoned that
LD could be present in the population sample at markers
surrounding any true BP-I loci identified in the pedigree
study. LD screening of patients with BP-I, in this pop-
ulation, might also yield important BP-I loci that were
not identified in the pedigree study. Pedigree-based link-
age studies involve selection of certain subsets (individ-
ual families) of the population in which there is a clus-
tering of affected individuals. In a complex disease, such
studies may be useful in finding genes of large effect in
those particular subsets, but they might not identify loci
that are important in understanding the basis of the dis-
ease in the general population. In this LD screen of chro-
mosome 18 in Costa Rican patients with BP-I, two
regions were highlighted as being of particular interest,
and both regions correspond to segments highlighted in
the previous pedigree studies from Costa Rica.
We previously highlighted the 18q22-23 chromoso-
mal region (Freimer et al. 1996a) because this area
showed the strongest evidence suggestive of linkage in
the two pedigrees of any region tested in a genome screen
conducted with ∼500 microsatellite markers (McInnes
et al. 1996). In the pedigree study, portions of a hap-
lotype of 140 cM in this region were shared by 22 of
26 individuals with BP-I (Freimer et al. 1996a), although
formal LOD scores for markers in this area were below
the level of significance required for proof of linkage. In
the current study, five markers in the 18q22-23 region
provide possible evidence of LD in Costa Rican patients
with BP-I. The marker that gave the strongest evidence
of possible LD in the current study, D18S1121, is located
within the 3-cM region of highest haplotype sharing ob-
served in the individuals with BP-I from the pedigree
study. The specific allele (of 168 bp), which is over-
represented on the disease chromosomes at this locus
(D18S1121) in the sample of the population with BP-I,
is also the allele that occurs on the putative high-risk
haplotype within the pedigrees (Freimer et al. 1996a).
Our pedigree studies had also highlighted a region at
18pter deserving of further study (McInnes et al. 1996),
albeit in only one of the two families, CR001. The sec-
ond-highest LOD score in the genome observed for fam-
ily CR001 was at D18S59, located near 18pter, and a
nearby marker, D18S476, also gave a positive LOD
score in this family. This current study of 48 patients
with BP-I now provides additional evidence for a BP-I
locus in this region, with the same two markers showing
evidence of LD. Because genomewide significance levels
have yet to be calculated for LD tests (Kruglyak 1997),
we can at present only interpret the evidence for LD in
the 18pter region (a pointwise P value of .002 formarker
D18S59) as being roughly equivalent to Lander and
Kruglyak’s criteria for suggestive, but not significant,
linkage in a genomewide screen (Lander and Kruglyak
1995). The alleles at D18S59 and D18S476 that are
overrepresented among the patients with BP-I, from the
population sample (154 and 271 bp, respectively), are
also overrepresented in the patients with BP-I from ped-
igree CR001 (all patients with BP-I in family CR001
have at least one copy of the 154 allele at D18S59),
possibly indicating that the patients with BP-I in the
pedigree share this region IBD with those 48% of pa-
tients with BP-I from the population sample who also
carry this haplotype.
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The third region that showed possible evidence of LD
in our population sample was identified through a single
marker (D18S467), in the 18q12.3 region. Additional
markers typed near this one did not support the initial
suggestion of LD in this region. Evidence from a linkage
test that yielded a significance level of would beP  .06
expected to occur, by chance, ∼24 times (about once on
most chromosomes) in a genomewide screen.
Our possible BP-I localizations at 18pter and 18q22-
23, in the current sample, are distinct from regions on
chromosome 18 suggested by other groups as being pos-
sibly linked to mood disorder (Berretini et al. 1994; Stine
et al. 1995). We detected no evidence of associationwith
these areas (near the centromere and in 18q21) in our
BP-I population sample; nevertheless, the power of our
current sample is not great enough to rule out these
regions as potential BP-I loci in the Costa Rican pop-
ulation. McMahon et al. (1997) have recently reported
excess allele sharing in sib pairs at 18S541, which is in
the 18q22-23 region, although their affected status in-
cluded not only BP-I, but also bipolar type II and schi-
zoaffective patients.
Future Directions
The results of this study suggest that shared-seg-
ment–screening approaches will only be useful with the
development of denser marker maps (Collins et al. 1997)
and with the development of tests that permit statistical
comparison of disease-chromosome haplotypes with
control-chromosome haplotypes. Because the potential
advantages of a shared-segment approach are substantial
(this type of approach takes maximum advantage of the
fact that haplotypes, not just single alleles, are inherited
IBD in population isolates, and it is nonparametric), and
because marker maps (Dib et al. 1996; Yuan et al. 1997)
and statistical methods continue to improve, we remain
optimistic about this method of mapping genes for com-
plex disorders.
Both the 18pter and the 18q22-23 regions would have
been identified as regions with possible LD at a signif-
icance of even if we had not used the shared-P ! .05,
segment approach but had instead screened for evidence
by using only the likelihood-ratio test, with the original
26 markers. Our results indicate that, in population iso-
lates, such as the CRCV, and with suitably dense marker
coverage, tests similar to the likelihood-ratio test of LD
(Terwilliger 1995) are promising tools for genome
screening of complex diseases. It is not clear, however,
whether currently available tests will be powerful
enough to detect unequivocal proof of association in a
genomewide scan for such diseases, given sample sizes
that are easily obtained. More-powerful tests are needed
and may emerge from efforts to develop measures that
make use of haplotype information (Service et al. 1999
[in this issue]; Durham and Feingold 1997; Goldin and
Chase 1997).
The test of LD screening conducted in the current
study points out the need to do a more complete LD
screening analysis. We thus intend to perform an LD
screen of chromosome 18, using an expanded sample of
patients with BP-I and a denser marker map. The ad-
dition of more-polymorphic markers to genome maps,
and the application of haplotype-based statistical tests
currently under development, should facilitate efforts to
definitively identify BP-I susceptibility genes in Costa
Rica.
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